Clinical trialNo phase (not a drug trial)Active not recruiting
Management of Symptomatic Advanced Pancreatic Adenocarcinoma
Management of Symptomatic Advanced Pancreatic Adenocarcinoma: "Urgence Pancreas" - A Prospective A.R.CA.D Cohort Study
- Outcome
- Ongoing
- Phase
- No phase (not a drug trial)
- Status
- Active not recruiting
- Study type
- Interventional
- Start
- 19 December 2016
- Listed end
- September 2025
- Enrollment
- 110 participants
- Sites
- 12
- Primary outcomes
- The rate of 14-EISCP success
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 13 June 2025
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study assessed the feasibility and effects of an early integrative supportive care program in patient with advanced pancreatic adenocarcinoma (aPDAC).
Detailed description public domain (ClinicalTrials.gov)
This is a national, multicenter, prospective study, including: * A 14-day (+/-2 days) integrative supportive care program (14-EISCP) initiated as early as the clinical suspicion of aPDAC, * Follow-up period after the 14-EISCP. ECOG PS ≥2 patients with pathologically confirmed or suspected aPDAC on imaging were included at first oncology visit in the 14-EISCP including pain, nutritional, diagnostic and stenting procedures. Post-EISCP ECOG PS ≤1 patients received mFOLFIRINOX or gemcitabine/nab-paclitaxel, ECOG PS ≥2 patients received mFOLFOX7 or investigator choice chemotherapy or best supportive care.